Skip to main content
logo
Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
5.13
+0.03 (0.49%)
Sep 3, 2026, 1:49 PM EDT - Market open

Arbutus Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
181.7214.086.1718.1439.0210.99
Revenue Growth
1078.78%128.21%-65.98%-53.51%255.11%58.92%
Gross Profit
163.92-11.16-47.87-55.56-45.39-54.51
Operating Income
147.43-27.05-69.97-78.03-63.22-71.65
Net Income
153.05-33.5-69.92-72.85-69.46-88.39
Earnings Per Share
0.79-0.17-0.38-0.44-0.46-0.83
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
92.6391.47122.62132.29184.28191.01
Total Debt
3.634.196.128.7212.5518.91
Net Cash (Debt)
8987.28116.51123.57171.72172.1
Net Cash Growth
-4.39%-25.08%-5.71%-28.04%-0.22%70.85%
Net Cash Per Share
0.460.460.630.741.141.62

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-24.63-39.64-64.85-85.94-35.36-67.53
Capital Expenditures
---0.18-1.01-0.51-0.81
Free Cash Flow
-24.63-39.64-65.03-86.94-35.87-68.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
90.20%-79.23%---116.32%-
Operating Margin
81.13%-192.08%-1133.92%-430.15%-162.03%-652.07%
Pretax Margin
84.23%-237.88%-1133.04%-401.57%-166.62%-693.91%
Profit Margin
84.23%-237.88%-1133.04%-401.57%-178.01%-804.39%
FCF Margin
-13.55%-281.45%-1053.83%-479.27%-91.92%-621.96%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-236.87236.87236.87236.87236.87
PS Ratio
5.5565.69100.4123.119.3447.89